In a study focusing on early myelofibrosis (DIPSS low- or intermediate-1), baseline driver mutations did not affect the treatment response, but the presence of ASXL1 or SRSF2 had a deleterious impact [171]. The gene discussed is ASXL1; the disease is myelofibrosis.